Engineering Bacteria To Produce Interleukin-10(IL-10) For Anti-cancer Therapy

With the rapid development of immunotherapy,a new era of tumor therapy has begun presently.Recent advances in CAR-T cell therapy(Chimeric Antigen Receptor T Cell Therapy)have raised the hope that a cure might be within reach for many cancer types,especially for leukemia.However,challenges still remain for use of immunotherapy to treat malignant solid tumors.This further limits the development and clinical trials of immunotherapy.Therefore,how to expand the selection of immunotherapy and improve the therapeutic effect on malignant solid tumor has recently emerged as a key to achieve the breakthrough of immunotherapy.Through more than a century of development,bacterial anti-cancer therapy ushered in the era of synthetic biology.Synthetic bacteria can be fully endowed with the functions of targeting,treatment and spatiotemporal release,which is expected to be combined with tumor immunotherapy to achieve a more adequate effect of solid tumor intervention.Many studies have reported on the modification of bacteria to deliver anti-tumor agents and activate the proliferation and migration of immune cell to to kill cancer cells.At present,Il-10 has become a new member of anti-tumor agents in immunotherapy.IL-10 can activate CD8~+T cells and reverse the microenvironment of immunosuppression in.In this study,the probiotics Escherichia coli Nissle 1917 was used as the delivery vector to specifically release Il-10 within the tumor.The results showed that Nissle 1917 had a good tumor targeting ability in tumor-bearing mice model,and also had a certain inhibitory effect on the growth of solid tumor.Therefore,this study has developed a new research program in the field of immunotherapy,which also provides the possibility for clinic in the future,as a potential treatment option to benefit more patients.